

Katherine Beck

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8507344/publications.pdf>

Version: 2024-02-01

34
papers

2,231
citations

430874

18
h-index

526287

27
g-index

36
all docs

36
docs citations

36
times ranked

3248
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-world clinical and cost-effectiveness of community clozapine initiation: mirror cohort study. <i>British Journal of Psychiatry</i> , 2022, 221, 740-747.	2.8	6
2	Relationship Between Replay-Associated Ripples and Hippocampal N -Methyl-D-Aspartate Receptors: Preliminary Evidence From a PET-MEG Study in Schizophrenia. <i>Schizophrenia Bulletin Open</i> , 2022, 3, .	1.7	1
3	The Effects of Acute δ^9 -Tetrahydrocannabinol on Striatal Glutamatergic Function: A Proton Magnetic Resonance Spectroscopy Study. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2021, 6, 660-667.	1.5	1
4	N-methyl-D-aspartate receptor availability in first-episode psychosis: a PET-MR brain imaging study. <i>Translational Psychiatry</i> , 2021, 11, 425.	4.8	14
5	Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. <i>Lancet Psychiatry</i> , 2020, 7, 64-77.	7.4	506
6	Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia. <i>JAMA Network Open</i> , 2020, 3, e204693.	5.9	103
7	Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. <i>Lancet Psychiatry</i> , 2020, 7, 344-353.	7.4	147
8	Prevalence of treatment-resistant psychoses in the community: A naturalistic study. <i>Journal of Psychopharmacology</i> , 2019, 33, 1248-1253.	4.0	24
9	The effects of cannabinoid 1 receptor compounds on memory: a meta-analysis and systematic review across species. <i>Psychopharmacology</i> , 2019, 236, 3257-3270.	3.1	21
10	Modelling Continuous Arterial Blood Data from MR-Compatible Sampler in Simultaneous Pet-MRI Experiments. , 2019, , .		1
11	Comment on "In Vivo ^{18}F GE-179 Brain Signal Does Not Show NMDA-Specific Modulation with Drug Challenges in Rodents and Nonhuman Primates". <i>ACS Chemical Neuroscience</i> , 2019, 10, 768-772.	3.5	11
12	Synaptic loss in schizophrenia: a meta-analysis and systematic review of synaptic protein and mRNA measures. <i>Molecular Psychiatry</i> , 2019, 24, 549-561.	7.9	179
13	Defining the Locus of Dopaminergic Dysfunction in Schizophrenia: A Meta-analysis and Test of the Mesolimbic Hypothesis. <i>Schizophrenia Bulletin</i> , 2018, 44, 1301-1311.	4.3	187
14	Perinatal interventions for mothers and fathers who are survivors of childhood sexual abuse. <i>Child Abuse and Neglect</i> , 2018, 80, 9-31.	2.6	16
15	Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2018, 137, 39-46.	4.5	76
16	Brain-relevant antibodies in first-episode psychosis: a matched case-control study. <i>Psychological Medicine</i> , 2018, 48, 1257-1263.	4.5	22
17	42.1 BODY AND MIND: CARDIO-METABOLIC AND IMMUNE FUNCTION IN FIRST EPISODE PSYCHOSIS AND COMPARISON WITH CENTRAL NEUROFUNCTIONAL MEASURES. <i>Schizophrenia Bulletin</i> , 2018, 44, S68-S68.	4.3	0
18	S19. EVIDENCE OF THE LIPID PARADOX IN PSYCHOSIS: A META-ANALYSIS OF CHOLESTEROL AND TRIGLYCERIDE LEVELS IN FIRST EPISODE PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2018, 44, S330-S330.	4.3	2

#	ARTICLE	IF	CITATIONS
19	Impaired Glucose Homeostasis in First-Episode Schizophrenia. <i>JAMA Psychiatry</i> , 2017, 74, 261.	11.0	328
20	Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study. <i>Neuropsychopharmacology</i> , 2017, 42, 941-950.	5.4	98
21	First-Episode Schizophrenia and Diabetes Risk—Reply. <i>JAMA Psychiatry</i> , 2017, 74, 763.	11.0	1
22	Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis. <i>British Journal of Psychiatry</i> , 2017, 211, 339-349.	2.8	118
23	Targeting glutamate to treat schizophrenia: lessons from recent clinical studies. <i>Psychopharmacology</i> , 2016, 233, 2425-2428.	3.1	22
24	Autoantibodies to central nervous system neuronal surface antigens: psychiatric symptoms and psychopharmacological implications. <i>Psychopharmacology</i> , 2016, 233, 1605-1621.	3.1	54
25	Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive. <i>Schizophrenia Bulletin</i> , 2016, 42, 744-752.	4.3	174
26	Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms. <i>Journal of Psychopharmacology</i> , 2015, 29, 892-897.	4.0	51
27	Prevalence of serum N-methyl-d-aspartate receptor autoantibodies in refractory psychosis. <i>British Journal of Psychiatry</i> , 2015, 206, 164-165.	2.8	25
28	The practical management of refractory schizophrenia - the Maudsley Treatment Review and Assessment Team service approach. <i>Acta Psychiatrica Scandinavica</i> , 2014, 130, 427-438.	4.5	38
29	Optimising treatment of refractory schizophrenia. <i>Psychopharmacology</i> , 2013, 227, 373-374.	3.1	3
30	Mind the mortality gap: the importance of metabolic function in mental illnesses. <i>Psychopharmacology</i> , 2013, 230, 1-2.	3.1	1
31	Seclusion reviews. , 0, , 246-250.		1
32	Ward rounds. , 0, , 221-224.		0
33	Lithium toxicity. , 0, , 418-421.		0
34	Medical emergencies. , 0, , 401-404.		0